Literature DB >> 2484690

Interaction between NO donors and iloprost in human vascular smooth muscle, platelets, and leukocytes.

R J Gryglewski1, R Korbut, E Trabka-Janik, A Zembowicz, M Trybulec.   

Abstract

Endothelium-derived relaxing factor (EDRF) and donors of nitric oxide (NO) (glyceryl trinitrate, SIN-1--a metabolite of molsidomine--S-nitroso-N-acetyl-penicillamine, and sodium nitroprusside) but not prostacyclin and its analog, iloprost, relax strips of rabbit aorta. Strips of human coronary artery also relax when exposed to NO donors and prostacyclin; in this artery, SIN-1 and iloprost exert additive but not synergistic relaxant action. In mildly activated human platelets and leukocytes, SIN-1 and iloprost have a synergistic suppressive action. A similar synergistic thrombolytic effect between NO and prostacyclin was observed in whole rabbit blood in interactions with rabbit aortic endothelium. These findings suggest that because of this cell-selective synergism between NO donors and prostacyclin analogs, the concomitant use of molsidomine and iloprost for the treatment of ischemic heart and peripheral vascular disease should be attempted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2484690

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Endotoxin-induced vasodilatation in anaesthetized rat skin involves nitric oxide and prostaglandin synthesis.

Authors:  J B Warren; M L Coughlan; T J Williams
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil.

Authors:  G M Pieper; G J Gross
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

3.  Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo.

Authors:  J B Warren; S W Larkin; M Coughlan; R Kajekar; T J Williams
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.